Clinical Development Compound Screening Development Protein 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Overcoming sector challenges . Furthermore, the global need is about seven times greater than the US.
Drug Discovery World
FEBRUARY 22, 2024
Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Libra’s pipeline targets mechanisms that can mitigate protein pathology associated with CNS degenerative disorders.
Expert insights. Personalized for you.
52 
Let's personalize your content